Maxence Bloch

Maxence Bloch, a partner in Goodwin’s Private Equity Group, focuses his practice on mergers and acquisitions. His experience includes all type of M&A and Private Equity transactions (Mid and Large-cap) with a concentration on MBOs, LBOs, IPOs, public takeovers, build-ups, venture capital and growth capital. He also has a particular expertise in transactions in the life sciences, healthcare, and technology sectors.

Maxence also focuses on litigation matters before all courts relating to M&A transactions, equity financing, and shareholders’ disputes.

Prior to joining Goodwin in 2016, Maxence was a partner at King & Wood Mallesons (formerly SJ Berwin) in Paris. Previously, he practiced at Clifford Chance, where he helped establish its private equity team. Before that, he was a lawyer at Hausmann & Associés and at Thomas & Associés, and was seconded to the Valeo Group for two years.

Maxence’s recent transactions include advising:

• a consortium of new and existing investors comprised of IK Partners, Keensight Capital, Parquest Capital and GIC in the acquisition of the Unither group, a European pharmaceutical contract development and manufacturing organization.
• Cerba Healthcare, a leading player in medical diagnosis:
  • in welcoming EQT Private Equity as a new investor, as Partners Group exits.
  • in the acquisition of the Labexa group, an independent medical biology group.
  • in the acquisition of the Yourlab group, a clinical pathology group based in Western France.
• EMZ Partners and Sagard in the 4th LBO acquisition of Safic-Alcan, a French independent distributor of specialty chemicals, welcoming three new private equity funds, Equistone, IK Partners and GENEO Capital Entrepreneur.
• Eurazeo in signing an agreement with TowerBrook Capital Partners to become a reference shareholder in EFESO Management Consultants, a leading international pure player consulting group in industrial operations strategy and performance improvement.
• EW Healthcare Partners in the minority investment in Boiron Développement in order to partially finance the take private of Boiron SA, an independent, family-run pharmaceutical laboratory specializing in the production of very high quality homeopathic medicine.
• Groupe Gorgé, an industrial group specializing in high-technology, in the acquisition of iXblue, a leading global provider of innovative solutions for navigation, photonics, and maritime autonomy for both civil and defense applications.
• Latour Capital in a majority investment in the holding company of Pharmacie Lafayette (Hygie31), a major player in the health and wellness sector.
• PAI Partners in the acquisition of MyFlower, the holding company of Interflora, a flower delivery e-commerce company.
• Tikehau Capital in the €90 million funding of ChapsVision, a group specialized in the field of investigation and data analysis software in both cyber intelligence and marketing sectors.
• The sellers including LFPI and the management of Explinvest, on the sale of Explinvest, holding of Titanobel's group, a leading industrial explosives manufacturer and drilling, blasting and technical services provider based in France, to Incitec Pivot Limited.
• Vivalto Partners in the acquisition of the Vivalto Santé group, the third leading group of private hospitals in France.

Maxence is consistently recognized as a leader in his field by International and French preeminent, peer-reviewed publications:

• Top ranked in Band 1 in Private Equity: Mid-Market in the last edition of the Chambers Europe guide
• Top ranked as Leading Individual in Private Equity: LBO in the last edition of the Legal 500 EMEA guide
• Recommended in Corporate Law, Mergers & Acquisitions Law, and Private Equity Law in the last edition of Best Lawyers France

He was also recognized as valedictorian of Lauréat de l’Ordre des Avocats.

Maxence’s recent publications and speaking engagements include:

Publications

• Author, “Le seuil de 10 % sur le contrôle des investissements étrangers en France pourrait être durablement maintenu," Option Finance, January 2022
• Co-Author (with Céline Domenget-Morin), “Restructuring et Private Equity : maîtriser la nouvelle donne," Capital Finance, March 2020

Speaking Engagements

• Speaker at the Roundtable, “Contrôles des investissements étrangers : enjeux et pratiques dans les secteurs stratégiques,” Option Droit & Affaires, January 2023
• Speaker at the conference, “Le LBO, un marché aux nuances infinies?,” Les Echos Capital Finance, February 2022
• Panelist in the session, “Sorties de LBO : quelles bonnes pratiques?,” Les Rencontres Private Equity, Option Finance, March 2020
• Speaker at the conference, “Restructuring et Private Equity : Maîtriser la nouvelle donne,” Les Echos, February 2020
• Speaker at the conference, “Contrôle des investissements étrangers,” Les Echos, November 2018